Warner Chilcott Reports Operating Results for the Quarter Ended March 31, 2009 and...

Warner Chilcott Reports Operating Results for the Quarter Ended March 31, 2009
and Updates 2009 Full Year Guidance

Growth of DORYX, LOESTRIN 24 FE and ESTRACE CREAM drives solid earnings
growth.

ARDEE, Ireland, May 11 /PRNewswire-FirstCall/ -- Warner Chilcott Limited
(Nasdaq: WCRX) today announced its results for the quarter ended March 31,
2009. Revenue in the quarter ended March 31, 2009 totaled $246.0 million, an
increase of 7.2% over the prior year quarter. The primary drivers of the
increase in revenue were the net sales of DORYX, LOESTRIN 24 FE and ESTRACE
CREAM, which together contributed $24.8 million of revenue growth for the
quarter ended March 31, 2009, as compared to the prior year quarter. The
growth delivered by these products was partially offset by net sales declines
in certain other products, primarily DOVONEX and FEMHRT.

The Company reported net income of $43.3 million ($0.17 per diluted share) in
the quarter ended March 31, 2009, compared with net income of $33.7 million
($0.13 per diluted share) in the prior year quarter, an increase of 28.8%.
Cash net income ("CNI") in the quarter ended March 31, 2009 rose to $97.7
million, an increase of 17.9% over the prior year quarter.

References in this release to "cash net income" or "CNI" mean the Company's
net income adjusted for the after-tax effects of two non-cash items:
amortization (including impairments, if any) of intangible assets and
amortization (including write-offs, if any) of deferred loan costs related to
the Company's debt. Reconciliations from the Company's reported results in
accordance with US GAAP to CNI and adjusted EBITDA for all periods are
presented in the tables at the end of this press release.

Revenue
Revenue in the quarter ended March 31, 2009 was $246.0 million, an increase of
$16.5 million, or 7.2%, over the prior year quarter. The primary drivers of
the increase in revenue were the net sales of DORYX, LOESTRIN 24 FE and
ESTRACE CREAM, which together contributed $24.8 million of revenue growth for
the quarter ended March 31, 2009 compared to the prior year quarter. The
growth delivered by these products was partially offset by net sales declines
in certain other products, primarily DOVONEX and FEMHRT. Period over period
changes in the net sales of our products are a function of a number of factors
including changes in: market demand, gross selling prices, sales-related
deductions from gross sales to arrive at net sales and the levels of pipeline
inventories of our products held by our direct and indirect customers. The
Company uses IMS Health, Inc. estimates of filled prescriptions for our
products as a proxy for market demand.

Net sales of our oral contraceptive products increased $8.0 million, or 12.5%,
in the quarter ended March 31, 2009, compared with the prior year quarter.
LOESTRIN 24 FE generated revenues of $52.4 million in the quarter ended March
31, 2009, an increase of 11.7% compared with $46.9 million in the prior year
quarter. The increase in LOESTRIN 24 FE net sales over the prior year quarter
was primarily due to an increase in filled prescriptions of 8.1% and higher
average selling prices, offset in part by the impact of higher sales-related
deductions. FEMCON FE generated revenues of $12.9 million in the quarter ended
March 31, 2009, an increase of $2.1 million, or 20.2%, versus the prior year
quarter. The increase in FEMCON FE net sales was primarily due to an increase
in filled prescriptions of 15.8% and higher average selling prices compared to
the prior year quarter.

Net sales of our dermatology products increased $9.8 million, or 9.3%, in the
quarter ended March 31, 2009, compared to the prior year quarter. Net sales of
DORYX increased $15.3 million, or 43.4%, in the quarter ended March 31, 2009,
compared to the prior year quarter, primarily due to a 22.6% increase in
filled prescriptions, as well as higher average selling prices. The increase
in filled prescriptions of DORYX, primarily relating to DORYX 150 mg, was due
to increased promotional efforts behind DORYX 150 mg, including our recently
launched customer loyalty card program. The increase in filled prescriptions
of 22.6% is not fully reflective of the impact on net sales as the value per
DORYX 150 mg prescription is greater than the value of a filled prescription
of the other strengths. Net sales of TACLONEX decreased $0.3 million, or 0.8%,
to $36.6 million in the quarter ended March 31, 2009, compared to $36.9
million in the prior year quarter. As filled prescriptions on a per-gram basis
were essentially flat, net sales of TACLONEX decreased primarily due to higher
sales-related deductions during the quarter ended March 31, 2009 and a
contraction in pipeline inventories relative to the prior year period. This
decrease was partially offset by higher average selling prices in the quarter
ended March 31, 2009 as compared to the prior year quarter. Net sales of
DOVONEX decreased by $5.2 million, or 15.6%, in the quarter ended March 31,
2009, compared with the prior year quarter. The decline was due primarily to a
decrease in filled prescriptions of 24.6% and higher sales-related deductions,
offset partially by higher selling prices and an expansion of pipeline
inventories relative to the prior year quarter.

Net sales of our hormone therapy products increased $0.6 million, or 1.2%, in
the quarter ended March 31, 2009, compared with the prior year quarter. Net
sales of ESTRACE CREAM increased $4.0 million, or 20.7%, in the quarter ended
March 31, 2009 compared to the prior year quarter. The increase was primarily
due to an increase in filled prescriptions of 15.4% and higher average selling
prices, offset in part, by a contraction of pipeline inventories relative to
the prior year quarter. Net sales of FEMHRT decreased $3.3 million, or 20.8%,
in the quarter ended March 31, 2009 compared to the prior year quarter due to
a decrease in filled prescriptions of 14.7% and higher sales-related
deductions which were offset, in part, by higher average selling prices
compared to the prior year quarter.

Cost of Sales (excluding amortization of intangible assets)
Cost of sales increased $1.0 million, or 2.1%, in the quarter ended March 31,
2009, compared with the prior year quarter. Our gross profit margin, as a
percentage of total revenue increased to 80.2% in the quarter ended March 31,
2009 as compared to 79.2% in the prior year quarter primarily due to changes
in the mix of products sold, offset in part, by increases in manufacturing
costs.

Selling, General and Administrative ("SG&A") Expenses
SG&A expenses for the quarter ended March 31, 2009 were $46.8 million, a
decrease of $8.4 million, or 15.3%, from $55.2 million in the prior year
quarter. Advertising and Promotion ("A&P") expenses for the quarter ended
March 31, 2009 decreased $9.5 million, or 55.5%, compared with the prior year
quarter, due primarily to an $8.1 million decrease in direct-to-consumer
advertising and a decrease in other promotional spending. Selling and
distribution expenses for the quarter ended March 31, 2009 decreased $0.7
million, or 3.2%, compared to the prior year quarter primarily due to a
reduction in the size of our field sales forces beginning in the first quarter
of 2009. General, Administrative and Other ("G&A") expenses in the quarter
ended March 31, 2009 increased $1.8 million, or 12.8%, compared to the prior
year quarter, primarily due to an increase in compensation expenses, including
non-cash stock-based compensation, and an increase in professional fees.

Research and Development ("R&D")
Our investment in R&D for the quarter ended March 31, 2009 was $23.9 million,
an increase of $11.7 million, or 96.0%, compared with the prior year quarter.
Included in the quarter ended March 31, 2009 was a $9.0 million payment to
Dong-A PharmTech Co. Ltd. upon the achievement of a developmental milestone
under our existing agreement for udenafil, an orally administered product for
the treatment of erectile dysfunction ("ED"). Also included in the quarter
ended March 31, 2009 was a $2.5 million payment to NexMed Inc. in connection
with our acquisition of the rights to its topically applied alprostadil cream
for the treatment of ED. Excluding the $11.5 million of milestones costs
during the quarter ended March 31, 2009, R&D expenditures were essentially
flat as compared to the prior year quarter. During the quarter ended March 31,
2009, the Company submitted a New Drug Application for a low-dose oral
contraceptive to the Food and Drug Administration.

Net Interest Expense
Net interest expense for the quarter ended March 31, 2009 was $18.0 million, a
decrease of $6.0 million, or 25.0%, from $24.0 million in the prior year
quarter. Included in net interest expense in the quarter ended March 31, 2009
was $1.3 million relating to the write-off of deferred loan costs associated
with the optional prepayment of $100.0 million of indebtedness under our
senior secured credit facility. We did not make any optional prepayments of
debt during the quarter ended March 31, 2008. The decrease in net interest
expense in the quarter ended March 31, 2009 was primarily the result of
cumulative reductions in outstanding debt during 2008 which reduced the
average debt balance outstanding from $1,200.2 million in the quarter ended
March 31, 2008 to $962.6 million in the quarter ended March 31, 2009. The
cumulative reduction in the average debt level is the result of optional
prepayments and purchases made using cash flows from operations and cash on
hand, net of investing activities.

Net Income and Cash Net Income
For the quarter ended March 31, 2009, reported net income was $43.3 million,
or $0.17 per share, and CNI was $97.7 million, or $0.39 per share, based on
250.6 million diluted Class A common shares outstanding. In calculating CNI,
we add back the after-tax impact of the amortization (including impairments,
if any) of intangible assets and the amortization (including write-offs, if
any) of deferred loan costs. These items are tax-effected at the estimated
marginal rates attributable to them. In the quarter ended March 31, 2009, the
marginal tax rate associated with the amortization of intangible assets was
8.4% and the marginal tax rate for amortization (including write-offs) of
deferred loan costs was 16.0%.

Liquidity, Balance Sheet and Cash Flows
As of March 31, 2009, our cash and cash equivalents totaled $30.3 million and
our total debt outstanding was $861.0 million. There were no borrowings
outstanding under the revolving portion of our senior secured credit facility.
We generated $105.3 million of cash from operating activities in the quarter
ended March 31, 2009, compared with net cash used in operating activities of
$(2.7) million in the prior year quarter, an increase of $108.0 million.
During the quarter ended March 31, 2009, the Company made payments in respect
of income taxes totaling $9.9 million as compared to $69.3 million in the
prior year quarter. Also impacting our cash flows from operating activities
relative to the prior year quarter was a $9.0 million cash payment made in the
quarter ended March 31, 2008 relating to the final settlement for our OVCON 35
litigation which was included in net income in the year ended December 31,
2007.

2009 Financial Guidance Update
Based on the first quarter results and current outlook for the remainder of
2009, the Company is affirming its full year 2009 financial guidance for
revenue, CNI and CNI per share. For 2009, the Company continues to anticipate
revenue to be in the range of $1,015 to $1,025 million, CNI to be in the range
of $390 to $402 million and CNI per share to be in the range of $1.55 to
$1.60.

The Company is updating the ranges for certain income statement expense items
for the full year 2009. Total SG&A expenses are now expected to be in the
range of $203 to $212 million, an increase of $4 million from the original
guidance given in January 2009. This primarily reflects an increase in
estimated professional fees attributable to the proposal being submitted to
shareholders of the Company to approve a Scheme of Arrangement as a result of
which a new principal holding company will be formed in Ireland and each
holder of the Company's Class A common shares, par value $0.01 per share, will
receive ordinary shares, par value $0.01 per share, in the new Irish holding
company on a one-for-one basis. The increase is offset in part by lower
selling and A&P expenses due to the reduction in sales forces beginning in the
first quarter of 2009.

Changes to the Company's full year 2009 guidance are summarized on the last
page which is attached as an exhibit to this release.

Investor Conference Call
The Company is hosting a conference call open to all interested parties, on
Monday, May 11, 2009 beginning at 8:00 AM EDT. The number to call within the
United States and Canada is (877) 879-6207. Participants outside the United
States and Canada should call (719) 325-4776. A replay of the conference call
will be available for two weeks following the call and can be accessed by
dialing (888) 203-1112 from within the United States and Canada or (719)
457-0820 from outside the United States and Canada. The replay ID number is
6475431.

The Company
Warner Chilcott is a leading specialty pharmaceutical company currently
focused on the women's healthcare and dermatology segments of the U.S.
pharmaceuticals market. The Company is a fully integrated company with
internal resources dedicated to the development, manufacturing and promotion
of its products. WCRX-F

Important Information for Stockholders
This communication is for informational purposes only and is not a substitute
for any proxy solicitation statement and related documents Warner Chilcott
Limited (the "Company") may file with the Securities and Exchange Commission
("SEC") in connection with the proposed transaction.

Investors and stockholders are urged to read any such documents filed with the
SEC carefully in their entirety when they become available because they will
contain important information about the proposed transaction.

Investors and stockholders may obtain these documents free of charge at the
website maintained by the SEC at www.sec.gov. In addition, documents filed
with the SEC by or on behalf of the Company will be available free of charge
by contacting Warner Chilcott Limited at (973) 442-3281 or emailing
rfuhrmann@wcrx.com.

The Company and its directors and executive officers and other members of
management and employees may be deemed to be participants in the solicitation
of proxies from stockholders of the Company in connection with the proposed
transaction. Information about the Company's directors and executive officers
is available on the internet at www.wcrx.com. Additional information regarding
the interests of such potential participants in a proxy solicitation will be
included in any proxy solicitation statement and other related documents that
may be filed by the Company with the SEC.

Forward Looking Statements
This press release contains forward-looking statements, including statements
concerning our operations, our economic performance and financial condition,
and our business plans and growth strategy and product development efforts.
These statements constitute forward-looking statements within the meaning of
Section 27A of the Securities Act of 1933 and Section 21E of the Securities
Exchange Act of 1934. The words "may," "might," "will," "should," "estimate,"
"project," "plan," "anticipate," "expect," "intend," "outlook," "believe" and
other similar expressions are intended to identify forward-looking statements.
Readers are cautioned not to place undue reliance on these forward-looking
statements, which speak only as of their dates. These forward-looking
statements are based on estimates and assumptions by our management that,
although we believe to be reasonable, are inherently uncertain and subject to
a number of risks and uncertainties. The following represent some, but not
necessarily all, of the factors that could cause actual results to differ from
historical results or those anticipated or predicted by our forward-looking
statements: our substantial indebtedness; competitive factors in the industry
in which we operate (including the approval and introduction of generic or
branded products that compete with our products); our ability to protect our
intellectual property; a delay in qualifying our manufacturing facility to
produce our products or production or regulatory problems with either third
party manufacturers upon whom we may rely for some of our products or our own
manufacturing facilities; pricing pressures from reimbursement policies of
private managed care organizations and other third party payors, government
sponsored health systems, the continued consolidation of the distribution
network through which we sell our products, including wholesale drug
distributors and the growth of large retail drug store chains; the loss of key
senior management or scientific staff; adverse outcomes in our outstanding
litigation or an increase in the number of litigation matters to which we are
subject; government regulation affecting the development, manufacture,
marketing and sale of pharmaceutical products, including our ability and the
ability of companies with whom we do business to obtain necessary regulatory
approvals; our ability to manage the growth of our business by successfully
identifying, developing, acquiring or licensing new products at favorable
prices and marketing such new products; our ability to obtain regulatory
approval and customer acceptance of new products, and continued customer
acceptance of our existing products; changes in tax laws or interpretations
that could increase our consolidated tax liabilities; the other risks
identified in our Annual Report on Form 10-K for the year ended December 31,
2008; and other risks detailed from time-to-time in our public filings,
financial statements and other investor communications.

We caution you that the foregoing list of important factors is not exclusive.
In addition, in light of these risks and uncertainties, the matters referred
to in our forward-looking statements may not occur. We undertake no obligation
to publicly update or revise any forward-looking statement as a result of new
information, future events or otherwise, except as may be required by law.

Reconciliations to GAAP Net Income

CNI
To supplement its condensed consolidated financial statements presented in
accordance with US GAAP, the Company provides a summary to show the
computation of CNI. CNI is defined as the Company's GAAP net income adjusted
for the after-tax effects of two non-cash items: amortization (including
impairments, if any) of intangible assets and amortization (including
write-offs, if any) of deferred loan costs related to the Company's debt. The
Company believes that the presentation of CNI provides useful information to
both management and investors concerning the approximate impact of the above
items. The Company also believes that considering the effect of these items
allows management and investors to better compare the Company's financial
performance from period-to-period, and to better compare the Company's
financial performance with that of its competitors. The presentation of this
additional information is not meant to be considered in isolation of, or as a
substitute for, results prepared in accordance with US GAAP.

Adjusted EBITDA
To supplement its condensed consolidated financial statements presented in
accordance with US GAAP, the Company is providing a summary to show the
computation of adjusted earnings before interest, taxes, depreciation and
amortization ("EBITDA") taking into account certain charges that were taken
during the quarters ended March 31, 2009 and 2008. The computation of adjusted
EBITDA is based on the definition of EBITDA contained in the indenture
governing the Company's Senior Subordinated Notes due 2015.

WARNER CHILCOTT LIMITED
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(In thousands of U.S. dollars, except per share amounts)
(Unaudited)

Quarter Ended
Mar-31-09 Mar-31-08
REVENUE:
Product net sales $239,024 $223,700
Other revenue 6,965 5,783
Total revenue 245,989 229,483

COSTS & EXPENSES:
Cost of sales (excludes amortization) 48,750 47,770
Selling, general and administrative 46,766 55,227
Research and development 23,872 12,180
Amortization of intangible assets 56,993 52,613
Net interest expense 18,017 24,018
INCOME BEFORE TAXES 51,591 37,675
Provision for income taxes 8,255 4,017

NET INCOME $43,336 $33,658

Earnings per share:
Class A - Basic $0.17 $0.13

Class A - Diluted $0.17 $0.13

RECONCILIATIONS:
Net income - GAAP $43,336 $33,658
+ Amortization of intangible assets, net of
tax 52,218 47,906
+ Amortization and write-offs of deferred
loan costs, net of tax 2,156 1,302
Cash net income $97,710 $82,866

WARNER CHILCOTT LIMITED
CONDENSED CONSOLIDATED BALANCE SHEETS
(In thousands of U.S. dollars)
(Unaudited)

As of As of
March 31, 2009 December 31, 2008
ASSETS
Current assets:
Cash & cash equivalents $30,308 $35,906
Accounts receivable, net 82,793 93,015
Inventories 61,478 57,776
Prepaid expenses & other current
assets 76,994 69,813

Total current assets 251,573 256,510

Other assets:
Property, plant and equipment, net 63,357 60,908
Intangible assets, net 939,705 993,798
Goodwill 1,250,324 1,250,324
Other non-current assets 18,797 21,351

TOTAL ASSETS $2,523,756 $2,582,891

LIABILITIES
Current liabilities:
Accounts payable $14,767 $15,014
Accrued expenses & other current
liabilities 149,424 151,753
Current portion of long-term debt 4,935 5,977

Total current liabilities 169,126 172,744

Other liabilities:
Long-term debt, excluding current
portion 856,128 956,580
Other non-current liabilities 100,842 103,647

Total liabilities 1,126,096 1,232,971

SHAREHOLDERS' EQUITY 1,397,660 1,349,920

TOTAL LIABILITIES & SHAREHOLDERS' EQUITY $2,523,756 $2,582,891

WARNER CHILCOTT LIMITED
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(in thousands of U.S. dollars)
(Unaudited)

Quarter Ended
Mar-31-09 Mar-31-08
CASH FLOWS FROM OPERATING ACTIVITIES:
Net income $43,336 $33,658
Adjustments to reconcile net income to
net cash provided by / (used in)
operating activities:
Depreciation 3,026 2,925
Amortization of intangible assets 56,993 52,613
Amortization of deferred loan costs 2,566 1,559
Stock compensation expense 2,632 1,810
Changes in assets and liabilities:
Decrease / (increase) in accounts
receivable, prepaid and other assets 3,882 (8,614)
(Increase) in inventories (3,702) (6,706)
(Decrease) in accounts payable,
accrued expenses & other current
liabilities (1,517) (13,832)
(Decrease) in income taxes and
other, net (1,857) (66,095)

Net cash provided by / (used in)
operating activities $105,359 $(2,682)

CASH FLOWS FROM INVESTING ACTIVITIES:
Purchase of intangible assets (2,900) (2,900)
Capital expenditures (6,548) (6,945)

Net cash (used in) investing activities $(9,448) $(9,845)

CASH FLOWS FROM FINANCING ACTIVITIES:
Term repayments under bank senior
secured credit facility (101,494) (2,071)
Other (15) 61

Net cash (used in) financing activities $(101,509) $(2,010)

Net (decrease) in cash and cash
equivalents $(5,598) $(14,537)
Cash and cash equivalents, beginning
of period 35,906 30,776
Cash and cash equivalents, end of
period $30,308 $16,239

WARNER CHILCOTT LIMITED
Reconciliation of Net Income to Adjusted EBITDA
(In thousands of U.S. dollars)
(Unaudited)

Quarter Ended
Mar-31-09 Mar-31-08
RECONCILIATION TO ADJUSTED EBITDA:
Net income - GAAP $43,336 $33,658

+ Interest expense, net 18,017 24,018
+ Provision for income taxes 8,255 4,017
+ Non-cash stock-based compensation expense 2,632 1,810
+ Depreciation 3,026 2,925
+ Amortization of intangible assets 56,993 52,613
+ R&D milestone payments 11,500 -

Adjusted EBITDA of WCL, as defined $143,759 $119,041

+ Expenses of WCL and other 2,373 1,801

Adjusted EBITDA of Warner Chilcott Holdings
Company III, Limited., as defined $146,132 $120,842

Note: Warner Chilcott Holdings Company III, Limited and certain of its
subsidiaries are parties to our credit agreement and the indenture
governing our 8.75% Senior Subordinated Notes due 2015. Certain expenses
included in Warner Chilcott Limited's ("WCL") consolidated operating
results are not deducted in arriving at Adjusted EBITDA for Warner
Chilcott Holdings Company III, Limited and its subsidiaries.

WARNER CHILCOTT LIMITED
REVENUE BY PRODUCT
(In millions of U.S. dollars)
(Unaudited)

Quarter Ended
Mar-31-09 Mar-31-08

Oral Contraceptives ("OC")
LOESTRIN 24 FE $52.4 $46.9
FEMCON FE 12.9 10.8
ESTROSTEP FE* 5.1 4.7
OVCON* 2.7 2.7

Total OC 73.1 65.1

Hormone therapy ("HT")
ESTRACE Cream 23.2 19.2
FEMHRT 12.7 16.0
FEMRING 3.8 3.5
Other HT products 2.5 2.9

Total HT 42.2 41.6

Dermatology
DORYX 50.4 35.1
TACLONEX 36.6 36.9
DOVONEX* 28.0 33.2

Total Dermatology 115.0 105.2

PMDD
SARAFEM 4.1 4.4

Other product net sales
Other 0.9 0.2
Contract manufacturing 3.7 7.2

Total product net sales 239.0 223.7

Other revenue
Royalty revenue 7.0 5.8

Total revenue $246.0 $229.5

* Includes revenue from related authorized generic product sales from the
date of their respective launch.

WARNER CHILCOTT LIMITED
SUMMARY OF SG&A EXPENSES
(In millions of U.S. dollars)
(Unaudited)

Quarter Ended
Mar-31-09 Mar-31-08

A&P $7.7 $17.2
Selling & distribution 22.9 23.6
G&A 16.2 14.4

Total SG&A $46.8 $55.2

Warner Chilcott Limited
2009 Full Year Financial Guidance
(U.S. dollars in millions, except per share amounts)

Original Guidance Revised Guidance
January 2009 May 2009

Total Revenue (1) $1,015 to $1,025 $1,015 to $1,025

Gross margin as a % of total revenue 79% to 80% 79% to 80%

SG&A Expenses:
--------------
A&P $44 to $47 $41 to $44
Selling & Distribution $91 to $94 $84 to $87
G&A $64 to $67 $78 to $81
Total SG&A Expenses (2) $199 to $208 $203 to $212

Total R&D (3) $77 to $80 $77 to $80

GAAP Net Income (4) $174 to $186 $174 to $186

CNI (5) $390 to $402 $390 to $402

CNI per share (5) (6) $1.55 to $1.60 $1.55 to $1.60

--------------
(1) Our 2009 guidance does not account for the impact of any future new
licensing agreements.
(2) Total SG&A expenses do not include any amount that may be payable in
connection with the potential settlement of our outstanding legal
actions.
(3) Total 2009 R&D expense consists of internal R&D anticipated to be in
the range of $61.5 to $64.5 million. Included in total 2009 R&D
expense are $11.5 million of milestone payments expensed during the
quarter ended March 31, 2009, as well as $4.0 million of anticipated
future milestone payments.
(4) The effective GAAP tax rate for 2009 is expected to be in the mid-to-
high teens.
(5) A reconciliation of 2009 GAAP net income to CNI adds back the expected
after tax impact of amortization of intangibles ($209M) and the
expected after tax impact of the amortization and write-offs of
deferred loan costs ($7M).
(6) CNI per share is based on 251.4 million fully diluted Class A shares.

SOURCE Warner Chilcott Limited

Rochelle Fuhrmann, Investor Relations, Warner Chilcott Limited,
+1-973-442-3281, rfuhrmann@wcrx.com